China has ordered 7.3 million doses of H1N1 flu vaccine from two domestic manufacturers: 3.3 million does from Sinovac (北京科兴生物制品有限公司) and 4 million doses from Hualan Biological Engineering Inc. Also, China granted emergency approval for Relenza (zanamivir), a GlaxoSmithKline drug that is both a prophylaxis and treatment for influenza A and B. Simcere (先声药业) owns the exclusive right to market Relenza in China. More details...

Stock Symbols: (NYSE Amex: SVA) (NYSE: GSK) (NYSE: SCR)